Telavancin (Vibativ®)

Assessment Status Rapid Review Complete
Drug Telavancin
Brand Vibativ®
Indication For the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable.
Assessment Process
Rapid review completed 13/01/2015
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended